Very late stent thrombosis with newer drug-eluting stents: No longer an issue?;Trombosis muy tardía con nuevos stents farmacoactivos: ¿Ha dejado de ser un asunto relevante?

Revista Espanola de Cardiologia

Volumn 65, Issue 7, 2012, Pages 595-598

  De La Torre Hernández, José M ^a   Windecker, Stephan ^b  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b BERN UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG ELUTING STENT; EDITORIAL; MEDICAL LITERATURE; STENT THROMBOSIS; VERY LATE STENT THROMBOSIS;

EID: 84862888159     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/j.recesp.2012.01.017     Document Type: Article

References (24)

1. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, Van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-51.
2. Moreno R, Fernández C, Hernández R, Alfonso F, Angiolillo DJ, Sabaté M, et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol. 2005;45:954-9.
3. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369:667-78.
4. De la Torre-Hernández JM, Alfonso F, Hernández F, Elizaga J, Sanmartin M, Pinar E, et al. Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpañol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol. 2008;51:986-90.
5. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356:998-1008.
6. Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation. 2009;119:3198-206.
7. Brar SS, Leon MB, Stone GW, Mehran R, Moses JW, Brar SK, et al. Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis. J Am Coll Cardiol. 2009;53:1677-89.
8. Räber L, Windecker S. Primary percutaneous coronary intervention and risk of stent thrombosis: a look beyond the HORIZON. Circulation. 2011;123:1709-12.
9. Baber U, Mehran R, Sharma SK, Brar S, Yu J, Suh JW, et al. Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. J Am Coll Cardiol. 2011;58:1569-77.
10. Alfonso F, Fernandez C. Second-generation drug-eluting stents. Moving the field forward. J Am Coll Cardiol. 2011;58:26-9.
11. Planer D, Smits PC, Kereiakes DJ, Kedhi E, Fahy M, Xu K, et al. Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials. J Am Coll Cardiol Intv. 2011;4:1104-15.
12. Alfonso F, Fernandez C. Head to head randomized comparisons of limus-eluting coronary stents. J Am Coll Cardiol. 2011;58:1855-8.
13. Räber L, Jüni P, Nüesch E, Kalesan B, Wenaweser P, Moschovitis A, et al. Long-term comparison of everolimus-eluting and sirolimus-eluting stents for coronary revascularization. J Am Coll Cardiol. 2011;57:2143-51.
14. Sarno G, Lagerqvist B, James S; on behalf of all SCAAR investigators. Considerably lower risk of stent thrombosis and restenosis in "new generation" drug-eluting stents. A report from the nationwide complete Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Disponible en: http://www.escardio. org/about/press/press-releases/esc11-paris/Pages/lower- thrombosis-restenosis- risk-stents-scaar.aspx
15. De la Torre Hernández JM, Alfonso F, Gimeno F, Diarte JA, Lopez-Palop R, Pérez de Prado A, et al. Thrombosis of second-generation drug-eluting stents in real practice: results from the multicenter Spanish registry ESTROFA-2 (Estudio Español Sobre Trombosis de Stents Farmacoactivos de Segunda Generación-2). J Am Coll Cardiol Intv. 2010;3:911-9.
16. Hermiller JB, Rutledge DR, Sudhir K, Stone GW, Serruys PW, Mao VW, et al. Stent trombosis alter implantation of XIENCE V everolimus-eluting stent systems in on-label and off-label populations: pooled two-years results from seven XIENCE V coronary stent trials. J Am Coll Cardiol. 2011;58 Suppl B:B23.
17. Sabate M, Cequier A, Iñiguez A, Serra A, Hernandez-Antolin R, Mainar V, et al. The EXAMINATION Trial: a randomized comparison between everolimus-eluting stent and bare metal stent in patients with ST-segment elevation myocardial infarction. Disponible en: http://www.escardio.org/ congresses/esc-2011/ congress-reports/Pages/708-3-EXAMINATION.aspx
18. Leon MB, Nikolsky E, Cutlip DE, Mauri L, Liberman H, Wilson H, et al. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial. J Am Coll Cardiol Intv. 2010;3:1043-50.
19. Kandzari DE, Mauri L, Popma JJ, Turco MA, Gurbel PA, Fitzgerald PJ, et al. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). J Am Coll Cardiol Intv. 2011;4:543-50.
20. Rasmussen K, Maeng M, Kaltoft A, Thayssen P, Kelbaek H, Tilsted HH, et al. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet. 2010;375:1090-9.
21. Silber S, Windecker S, Vranckx P, Serruys PW. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet. 2011;377:1241-7.
22. Yeoung AC, Leon MB, Jain A, Tolleson TR, Spriggs DJ, Mc Laurin BT, et al; RESOLUTE US Investigators. Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial. J Am Coll Cardiol. 2011;57: 1778-83.
23. Kolandaivelu K, Swaminathan R, Gibson WJ, Kolachalama VB, Nguyen-Ehrenreich KL, Giddings VL, et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation. 2011;123:1400-9.
24. Navarese EP, Kubica J, Castriota F, Gibson CM, De Luca G, Buffon A, et al. Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials. EuroIntervention. 2011;7:985-94.